Open-Label Extension Study of UT-15C in Subjects With Pulmonary Arterial Hypertension- A Long-Term Follow-Up to Protocol TDE-PH-310
Phase of Trial: Phase III
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Therapeutic Use
- Sponsors United Therapeutics Corporation
- 13 Oct 2017 This study has been completed in Austria as per European Clinical Trials Database.
- 12 Feb 2015 Planned number of patients changed from 858 to 610 as reported by ClinicalTrials.gov record.
- 09 Oct 2014 New source identified and integrated (European Clinical Trials Database record:EudraCT2012-000098-21)